Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Overview
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is regarded as an orphan tumour due to its rareness and usual clinical aggressiveness with poor response to conventional chemotherapies. It derives from precursors of plasmacytoid dendritic cells (pDCs), also known as professional type I interferon-producing cells or plasmacytoid monocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, BPDCN is quoted after acute myeloid leukaemia. This reflects the fact that the gene signature of the cell of origin is much closer to myeloid than lymphoid precursors. It has a dismal prognosis, with most patients dying within one year when treated by conventional chemotherapies. The diagnosis is challenging, since neoplastic cells can resemble lymphoblasts or small immunoblasts, and require the use of a large panel of antibodies, including those against CD4, CD56, CD123, CD303, TCL1, and TCF4. The morphologic and in part phenotypic ambiguity explains the uncertainties as to the histogenesis of the neoplasm that led to the use of various denominations.
“Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape is provided which includes the disease overview and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy treatment guidelines. The assessment part of the report embraces, in depth Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy R&D. The therapies under development are focused on novel approaches to treat/improve Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs Chapters
This segment of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs
IMGN 632: ImmunoGen
IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen’s (the “Company”) novel indolinobenzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.
The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020; IMGN632 also holds this designation in the US. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN.
Further product details are provided in the report……..
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Therapeutic Assessment
This segment of the report provides insights about the different Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
There are approx. 5+ key companies which are developing the therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy. The companies which have their Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drug candidates in the most advanced stage, i.e. phase I/II include, ImmunoGen
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Overview
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is regarded as an orphan tumour due to its rareness and usual clinical aggressiveness with poor response to conventional chemotherapies. It derives from precursors of plasmacytoid dendritic cells (pDCs), also known as professional type I interferon-producing cells or plasmacytoid monocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, BPDCN is quoted after acute myeloid leukaemia. This reflects the fact that the gene signature of the cell of origin is much closer to myeloid than lymphoid precursors. It has a dismal prognosis, with most patients dying within one year when treated by conventional chemotherapies. The diagnosis is challenging, since neoplastic cells can resemble lymphoblasts or small immunoblasts, and require the use of a large panel of antibodies, including those against CD4, CD56, CD123, CD303, TCL1, and TCF4. The morphologic and in part phenotypic ambiguity explains the uncertainties as to the histogenesis of the neoplasm that led to the use of various denominations.
“Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape is provided which includes the disease overview and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy treatment guidelines. The assessment part of the report embraces, in depth Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy R&D. The therapies under development are focused on novel approaches to treat/improve Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs Chapters
This segment of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs
IMGN 632: ImmunoGen
IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen’s (the “Company”) novel indolinobenzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.
The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020; IMGN632 also holds this designation in the US. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN.
Further product details are provided in the report……..
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Therapeutic Assessment
This segment of the report provides insights about the different Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
There are approx. 5+ key companies which are developing the therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy. The companies which have their Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drug candidates in the most advanced stage, i.e. phase I/II include, ImmunoGen
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Report Insights
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs?
- How many Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy and their status?
- What are the key designations that have been granted to the emerging drugs?
- AbbVie
- ImmunoGen
- Venetoclax
- IMGN 632
- Research programme: Allogeneic gene-edited chimeric antigen receptors T-cell therapy
Introduction
Executive Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I/II)
Comparative Analysis
IMGN632: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Research programme: Allogeneic gene-edited chimeric antigen receptors T-cell therapy: Allogene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Products
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Unmet Needs
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Market Drivers and Barriers
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Future Perspectives and Conclusion
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Analyst Views
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
Appendix
Executive Summary
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy : Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I/II)
Comparative Analysis
IMGN632: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
Research programme: Allogeneic gene-edited chimeric antigen receptors T-cell therapy: Allogene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Products
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Unmet Needs
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Market Drivers and Barriers
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Future Perspectives and Conclusion
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Analyst Views
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
